ライフサイエンスコーパス: granulomatosis

1 and one with toxoplasmosis plus lymphomatoid granulomatosis).

2 and glomerulonephritis (excluding Wegener's granulomatosis).

3 ulomatosis with polyangiitis (GPA, Wegener's granulomatosis).

4 ingham Vasculitis Activity Score for Wegener granulomatosis).

5 nervous system involvement from lymphomatoid granulomatosis.

6 implicated in the pathogenesis of Wegener's granulomatosis.

7 litis Activity Score, modified for Wegener's granulomatosis.

8 s for clinical care of patients with Wegener granulomatosis.

9 uction agent for severe refractory Wegener's granulomatosis.

10 a role in the etiopathogenesis of Wegener's granulomatosis.

11 such as microscopic polyangiitis and Wegener granulomatosis.

12 the lesions of patients with Langerhans cell granulomatosis.

13 lant recipients and 1 patient with Wegener's granulomatosis.

14 ted patients with limited forms of Wegener's granulomatosis.

15 ing aortitis, atherosclerosis, and Wegener's granulomatosis.

16 leptomeningeal biopsy demonstrated Wegener's granulomatosis.

17 zations among 571 individuals with Wegener's granulomatosis.

18 acy in severe vasculitis or severe Wegener's granulomatosis.

19 One of them is Wegener's granulomatosis.

20 osis was suggested to be a type of Wegener's granulomatosis.

21 och-Schonlein purpura, and A1AT in Wegener's granulomatosis.

22 th polyangiitis, formerly known as Wegener's granulomatosis.

23 its relevance to the diagnosis of Wegener's granulomatosis.

24 ic forms of damage associated with Wegener's granulomatosis.

25 tant concern for all patients with Wegener's granulomatosis.

26 e of morbidity among patients with Wegener's granulomatosis.

27 lasmic antibodies in patients with Wegener's granulomatosis.

28 o an initial mistaken diagnosis of Wegener's granulomatosis.

29 d, controlled trial in patients with Wegener granulomatosis.

30 NK-cell angiocentric lymphomas (lymphomatoid granulomatosis), 12/19 T-cell anaplastic large-cell lymp

31 a case of hepatosplenic necrotizing sarcoid granulomatosis, a variant form of "classical" sarcoidosi

32 than mature-PR3-ANCA as a measure of Wegener granulomatosis activity.

33 lomatous pathology, which we term "asthmatic granulomatosis." Although identification of this disease

34 d 10,771 hospitalizations included Wegener's granulomatosis among the discharge diagnoses.

35 mics the full spectrum of human lymphomatoid granulomatosis, an EBV-associated malignancy with no eff

36 62-year-old male with a history of Wegener's granulomatosis and immunosuppressive therapy presented w

37 aspects of the care of children with Wegener granulomatosis and microscopic polyangiitis are derived

38 nosis of such types of vasculitis as Wegener granulomatosis and microscopic polyangiitis.

39 scular damage from EBV-positive lymphomatoid granulomatosis and nasal or nasal-type T/natural killer

40 d in patients with EBV-positive lymphomatoid granulomatosis and nasal or nasal-type T/NK-cell lymphom

41 re often in a position to diagnose Wegener's granulomatosis and prevent significant morbidity.

42 hose of ELISA is highly specific for Wegener granulomatosis and related vasculitides even in patients

43 st a familial link between risk of Wegener's granulomatosis and rheumatoid arthritis.

44 ly unexpected associations between Wegener's granulomatosis and the incidence of malignancy, venous t

45 yclophosphamide for the treatment of Wegener granulomatosis and were followed for 0.5 to 27 years (me

46 th polyangiitis (formerly known as Wegener's granulomatosis) and microscopic polyangiitis.

47 PECAM-1 and it may have a role in Wegener's granulomatosis, and antibodies to HNA-2a frequently caus

48 e useful in preventing relapses in Wegener's granulomatosis, and patients develop fewer infections.

49 Sarcoidosis, Wegener granulomatosis, and pseudorheumatoid nodules must be rul

50 In Europe, Wegener granulomatosis appears to be more common at high latitud

51 systemic lupus erythematosus, and Wegener's granulomatosis are also reported.

52 in the geographic distribution of Wegener's granulomatosis are apparent when analysis consider rates

53 ing patterns of orbital disease in Wegener's granulomatosis are presented.

54 Granulomatous syndromes, such as Wegener's granulomatosis, are defined according to complex criteri

55 icates in the United States listed Wegener's granulomatosis as a cause of death.

56 cribe a patient who presented with Wegener's granulomatosis associated with antineutrophil cytoplasmi

57 New diagnosis of Wegener's granulomatosis at baseline was an independent predictor

58 roversy has arisen over the eponym Wegener's granulomatosis because of alleged involvement of Friedri

59 temic sclerosis, Takayasu arteritis, Wegener granulomatosis, Behcet syndrome, and transplant arterios

60 The syndrome resembles Wegener's granulomatosis both clinically and histologically.

61 ficiency and cutaneous Staphylococcus aureus granulomatosis (botryomycosis) in a cohort of related Sw

62 events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known.

63 rmingham Vasculitis Activity Score/Wegener's Granulomatosis (BVAS/WG)=0 off prednisone.

64 gham Vasculitis Activity Score for Wegener's granulomatosis [BVAS/WG] score of 0) at month 6.

65 This case illustrates that Wegener's granulomatosis can cause chronic meningitis.

66 ryllium is associated with a human pulmonary granulomatosis characterized by an accumulation of CD4(+

67 eryllium disease (CBD) is a hypersensitivity granulomatosis characterized by beryllium hypersensitivi

68 Study of other vasculitides, such as Wegener granulomatosis, Churg-Strauss syndrome, and microscopic

69 ain systemic conditions, including Wegener's granulomatosis, Cogan's syndrome, polyarteritis nodosa,

70 with systemic lupus erythematosis or Wegener granulomatosis did not differ from patients without cGVH

71 omarker for the autoimmune disease Wegener's granulomatosis, diluted up to 10(7)-fold in 1% human ser

72 During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-contro

73 lignancies was observed during the Wegener's Granulomatosis Etanercept Trial (WGET), which included 1

74 We evaluated data from the Wegener's Granulomatosis Etanercept Trial.

75 udy used the BVAS/WG data from the Wegener's Granulomatosis Etanercept Trial.

76 Although studies of Wegener's granulomatosis frequently focus on controlling disease a

77 dosa, hypersensitivity vasculitis, Wegener's granulomatosis, giant cell arteritis and Takayasu's arte

78 Lymphomatoid granulomatosis has a high rate of central nervous system

79 of systematic vasculitis, such as Wegener's granulomatosis, have circulating antineutrophil cytoplas

80 y; for example, most patients with Wegener's granulomatosis in China have myeloperoxidase-antineutrop

81 Other genes associated with Wegener's granulomatosis in replicated candidate gene studies are

82 The prevalence of Wegener's granulomatosis in the United States is approximately 3.0

83 olyangiitis (P = 2.9 x 10(-4)) and Wegener's granulomatosis in two independent cohorts from the UK (P

84 have systemic lupus erythematosus, Wegener's granulomatosis, inflammatory myopathy, or polyarteritis

85 Wegener's granulomatosis is a multisystem disease characterized by

86 ), the major target autoantigen in Wegener's granulomatosis is a serine proteinase that is normally s

87 evidence supports the notion that Wegener's granulomatosis is an autoimmune disease.

88 Standard therapy for Wegener's granulomatosis is fraught with substantial toxicity and

89 The incidence rate of VTEs in Wegener granulomatosis is high when compared with available rate

90 racteristic granuloma formation of Wegener's granulomatosis is unclear.

91 matosis with polyangiitis (GPA; or Wegener's granulomatosis) is the granulomatous inflammation of the

92 f clinical entities referred to as "familial granulomatosis." It is the sole human model with recogni

93 tis, systemic lupus erythematosis, Wegener's granulomatosis, juvenile dermatomyositis, juvenile scler

94 Thyroid disease, breast disease and granulomatosis lung disease were the most frequent cause

95 Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus-associ

96 Lymphomatoid granulomatosis (LyG) is an angiodestructive lymphoprolif

97 subset of vasculitis that includes Wegener's granulomatosis, microscopic polyangiitis (microscopic po

98 uses of orbital inflammation such as Wegener granulomatosis must be considered to prevent potentially

99 microscopic polyangiitis (n=43) or Wegener's granulomatosis (n=42).

100 and neck is most commonly caused by Wegener granulomatosis, natural killer/T-cell lymphomas, cocaine

101 le patients had newly diagnosed AAV (Wegener granulomatosis or microscopic polyangiitis) and were age

102 ANCA-positive patients with either Wegener's granulomatosis or microscopic polyangiitis.

103 diseases such as Crohn's disease, Wegener's granulomatosis, or sarcoidosis.

104 1990 ACR classification criteria for Wegener granulomatosis, polyarteritis nodosa, giant-cell arterit

105 vary considerably in patients with Wegener's granulomatosis, polyarteritis nodosa, microscopic polyan

106 tis, systemic lupus erythematosus, Wegener's granulomatosis, polymyositis, dermatomyositis, polyarter

107 A 56-year-old man with a history of Wegener granulomatosis presented with 6 days of sinus congestion

108 uide the management of patients with Wegener granulomatosis remains controversial.

109 ith polyangiitis (GPA), previously Wegener's granulomatosis, requires prompt diagnosis and systemic r

110 Within the Wegener's granulomatosis subgroup, the median VDI score for 12 non

111 inase 3 and neutrophil elastase in Wegener's granulomatosis, support the concept that there is a natu

112 a biopsy-confirmed diagnosis of lymphomatoid granulomatosis that evolved into fatal B-cell lymphoma o

113 asculitides is wide: For example, in Wegener granulomatosis the pattern ranges from cavitating nodule

114 In particular, in contrast to Wegener's granulomatosis, the need for routine cyclophosphamide tr

115 italizations/year in patients with Wegener's granulomatosis to 2 cases/10,000 hospitalizations/year i

116 Patients with Wegener's granulomatosis usually seek medical care for respiratory

117 incidence of VTE among patients with Wegener granulomatosis was 7.0 per 100 person-years (95% CI, 4.0

118 A diagnosis of Wegener's granulomatosis was considered in all of them, but abando

119 Wegener's granulomatosis was initially considered to be most likel

120 ies of the use of plasma exchange in Wegener granulomatosis was published.

121 An exacerbation of Wegener granulomatosis was the principal concern because of the

122 s with pathologically confirmed lymphomatoid granulomatosis were enrolled in a natural history and tr

123 Patients with Wegener's granulomatosis were excluded.

124 Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) h

125 for the small vessel vasculitides Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA).

126 Wegener's granulomatosis (WG) is a granulomatous vasculitis that a

127 Wegener's granulomatosis (WG) is a systemic inflammatory disease t

128 Wegener's granulomatosis (WG) is a systemic vasculitis of unknown

129 ecipitating event(s) that triggers Wegener's granulomatosis (WG) is unknown.

130 describes a case of severe limited Wegener's granulomatosis (WG) presenting in the third trimester of

131 chronic hepatitis C infection, and Wegener's granulomatosis (WG), an inflammatory, granulomatous vasc

132 he neutrophilic vasculitis seen in Wegener's granulomatosis (WG), are directed against proteinase-3 (

133 cytoplasmic antibodies (ANCAs) in Wegener's granulomatosis (WG).

134 lasmic antibody (cANCA)-associated Wegener's granulomatosis (WG).

135 approximately 60% of patients with Wegener's granulomatosis (WG).

136 a determinant of susceptibility to Wegener's granulomatosis (WG).

137 She was initially thought to have Wegener's granulomatosis (WG).

138 h CIMDL with that in patients with Wegener's granulomatosis (WG).

139 Total PSV, subgroups (47 Wegener's granulomatosis [WG], 12 microscopic polyangiitis, 16 Chu

140 hils or Th2 immune responses in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome

141 on the beneficial use of RTX in eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

142 Eosinophilic granulomatosis with polyangiitis (Churg-Strauss, EGPA) i

143 oscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA),

144 Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare system

145 oscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-S

146 condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly known as Wege

147 the subsequent activation of neutrophils in granulomatosis with polyangiitis (formerly Wegener disea

148 erence (CHCC) definition with categories for granulomatosis with polyangiitis (GPA) (Wegener's), micr

149 Lacrimal gland involvement in granulomatosis with polyangiitis (GPA) commonly accompan

150 Granulomatosis with polyangiitis (GPA) is a systemic nec

151 Granulomatosis with polyangiitis (GPA), previously Wegen

152 injury during autoimmune vasculitis, such as granulomatosis with polyangiitis (GPA).

153 The ANCA-associated vasculitides, granulomatosis with polyangiitis (GPA, formerly Wegener'

154 replicate the granulomatous lesions found in granulomatosis with polyangiitis (GPA, formerly Wegener'

155 es in development of systemic vasculitis and granulomatosis with polyangiitis (GPA, Wegener's granulo

156 A key feature of granulomatosis with polyangiitis (GPA; or Wegener's gran

157 remission in patients with chronic relapsing granulomatosis with polyangiitis (Wegener's) (GPA).

158 ve been repeatedly reported in patients with granulomatosis with polyangiitis (Wegener's) (GPA).

159 ial (WGET), which included 180 patients with granulomatosis with polyangiitis (Wegener's) (GPA).

160 Granulomatosis with polyangiitis (Wegener's) is a rare a

161 tanding the pathogenesis and presentation of granulomatosis with polyangiitis (Wegener's).

162 the use of rituximab (RTX) in patients with granulomatosis with polyangiitis (Wegener's; GPA), micro

163 omponent, shows genetic distinctions between granulomatosis with polyangiitis and microscopic polyang

164 ith ANCA-associated vasculitis and also that granulomatosis with polyangiitis and microscopic polyang

165 In contrast, neutrophils from patients with granulomatosis with polyangiitis expressing high membran

166 Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasc

167 was stratified by ANCA type, AAV diagnosis (granulomatosis with polyangiitis versus microscopic poly

168 ts with relapsing or refractory eosinophilic granulomatosis with polyangiitis who had received treatm

169 The 115 enrolled patients (87 with granulomatosis with polyangiitis, 23 with microscopic po

170 e target of anti-neutrophil cytoplasm Abs in granulomatosis with polyangiitis, a form of systemic vas

171 We describe a 15-year-old girl with granulomatosis with polyangiitis, formerly known as Wege

172 Proteinase 3 (PR3), the autoantigen in granulomatosis with polyangiitis, is expressed at the pl

173 In participants with eosinophilic granulomatosis with polyangiitis, mepolizumab resulted i

174 Patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiit

175 ression of PR3 is increased in patients with granulomatosis with polyangiitis, MVs generated from neu

176 th EM were hypersensitivity and eosinophilic granulomatosis with polyangiitis, which accounted for 34

177 isease, nonspecific orbital inflammation, or granulomatosis with polyangiitis.

178 gers, and clearers of the PR3 autoantigen in granulomatosis with polyangiitis.

179 3 anti-neutrophil cytoplasmic antibodies) in granulomatosis with polyangiitis.

180 have value in the treatment of eosinophilic granulomatosis with polyangiitis.

181 Finally, plasma exchange for Wegener granulomatosis with severe renal dysfunction appears not